CAYMAN ISLANDS - Silexion Therapeutics Corp. (NASDAQ: SLXN), a biotech firm focusing on RNA interference (RNAi) treatments, ...

Research co-led by University of Toronto researchers and Insilico Medicine has demonstrated the potential of quantum ...

Revolution Medicines' promising KRAS inhibitors show potential in pancreatic cancer. See why we recommend a hold rating on ...

SIL-204 administered in an extended release formulation reduced tumor growth by ~50% after 30 days, with ~50% of tumors showing complete necrosis, in human pancreatic tumors harboring a G12D mutation ...

With such volatility, SLXN has emerged as one of the most talked-about stocks of the day, creating a buzz in the biotechnology sector. Let’s dive into the details behind this remarkable movement and ...

Silexion Therapeutics shares preclinical data on SIL-204, highlighting tumor reduction in KRAS-driven cancers and sustained drug efficacy for 56+ days.

Approval is based on data from the Phase III CodeBreaK 300 trial, which demonstrated that treatment with Lumakras and ...

Quantum computing and artificial intelligence (AI) can be combined with classical computing methods to design and discover small-molecule candidates that target the cancer-driving KRAS protein, ...

Silexion Therapeutics (SLXN) announced new preclinical data for SIL-204, its next-generation siRNA therapeutic candidate. The findings ...

The FDA has approved Lumakras with Vectibix for adults with KRAS G12C-mutated metastatic colorectal cancer who received ...

The combination treatment specifically targets KRAS-mutated metastatic colorectal cancer (CRC) to improve progression-free ...

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS® (sotorasib) in ...